RecruitingRecruiting
A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care Mogamulizumab
NCT07003100 · City of Hope Medical Center
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
A Prospective, US-Based Study Assessing Mogamulizumab-Associated Rash in Patients Diagnosed With Mycosis Fungoides or Sézary Syndrome and Treated With Standard of Care Mogamulizumab
About this study
PRIMARY OBJECTIVE:
I. To assess the incidence of mogamulizumab-associated rash (MAR) and its association with overall response in patients with cutaneous T-cell lymphoma (CTCL); mycosis fungoides \[MF\] and sezary syndrome \[SS\] subtypes) treated with mogamulizumab.
OUTLINE: This is an observational study.
Patients complete questionnaires, have photographs of their skin taken, and undergo blood sample collection and skin biopsies on study. Patients' medical records are also reviewed.
Eligibility criteria
Inclusion Criteria:
* \* Adult patients (\>= 18 years of age) diagnosed with relapsed/refractory Mycosis Fungoides (MF) stage IB, IIA, IIB, III and IV or Sezary Syndrome(SS), and selected by their treating physician to receive single agent mogamulizumab (newly initiated)
* Signed informed consent
* Willing to undergo baseline biopsy and during treatment to evaluate for Mogamulizumab-Associated Rash (MAR) if clinically indicated
* Willing to provide blood sample at baseline, and if applicable, at onset of Mogamulizumab-Associated Rash (MAR)
Exclusion Criteria:
* \* Other concomitant systemic and skin directed Cutaneous T-cell Lymphoma (CTCL) regimens except for topical steroids
* Prior treatment with mogamulizumab
Study design
Enrollment target: 100 participants
Age groups: adult, older_adult
Timeline
Starts: 2024-12-06
Estimated completion: 2027-01-12
Last updated: 2026-11-04
Interventions
Other: Non-Interventional Study
Primary outcomes
- • Binary incidence of mogamulizumab-associated rash (MAR) (Up to 3 years)
Sponsor
City of Hope Medical Center · other
With: National Cancer Institute (NCI)
Contacts & investigators
InvestigatorChristiane Querfeld · principal_investigator, City of Hope Medical Center
All locations (10)
City of Hope Medical CenterRecruiting
Duarte, California, United States
Stanford Cancer Institute Palo AltoNot Yet Recruiting
Palo Alto, California, United States
Moffitt Cancer CenterNot Yet Recruiting
Tampa, Florida, United States
Emory University Hospital/Winship Cancer InstituteNot Yet Recruiting
Atlanta, Georgia, United States
Johns Hopkins University/Sidney Kimmel Cancer CenterNot Yet Recruiting
Baltimore, Maryland, United States
Brigham and Women's HospitalNot Yet Recruiting
Boston, Massachusetts, United States
Siteman Cancer Center at Washington UniversityRecruiting
St Louis, Missouri, United States
Thomas Jefferson University HospitalNot Yet Recruiting
Philadelphia, Pennsylvania, United States
M D Anderson Cancer CenterNot Yet Recruiting
Houston, Texas, United States
Fred Hutchinson Cancer CenterNot Yet Recruiting
Seattle, Washington, United States